86th Scientific Sessions of the American Diabetes Association (ADA 2026)
In this presentation, we will introduce SDT fatty/Jcl and share our latest conceptual findings regarding its metabolic characteristics. Particular emphasis will be placed on its relevance within the Cardiovascular–Kidney–Metabolic (CKM) framework and its potential utility in translational research addressing complex metabolic disorders.
The poster will also highlight the applicability of this model in studies involving GLP-1 receptor agonists, including semaglutide, and its role in supporting the evaluation of emerging therapeutic strategies. Through this work, we aim to contribute to a deeper understanding of integrated metabolic disease mechanisms and to facilitate more effective preclinical research approaches.
Key Word：
Cardiovascular–Kidney–Metabolic (CKM), Semaglutide, GLP-1 Receptor Agonist
- ADA 2026
- June 5 – 8 , 2026 , Ernest N. Morial Convention Center, New Orleans, LA, USA
Related CLEA Japan product: SDT fatty
For the animal model, please click here ▼
https://www.clea-japan.com/en/products/diabetes/item_a0150
Inquiry
If you have any questions, please feel free to contact us.
